Business Context and Reporting Period
Company: Protagonist Therapeutics, Inc. (PTGX)
Filing Type: Form 8-K (Current Report)
Reporting Date: March 8, 2025 (Earliest event reported)
Business Focus: Biopharmaceutical company developing icotrokinra for inflammatory diseases.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding clinical developments and does not contain audited financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Clinical Developments
- Plaque Psoriasis (March 8, 2025): The Company announced clinical study results for icotrokinra, stating the data demonstrates potential to shift the treatment paradigm and set a new standard for plaque psoriasis.
- Ulcerative Colitis (March 10, 2025): The Company announced positive top-line results from the Phase 2b ANTHEM-UC study of icotrokinra in patients with ulcerative colitis, suggesting potential to transform the treatment paradigm for this condition.
Guidance, Outlook, and Risks
Management Commentary: Management emphasizes the transformative potential of icotrokinra in both plaque psoriasis and ulcerative colitis based on the recent study results.
Outlook: An updated corporate presentation is available on the Company's website.
Risks and Contingencies: The filing explicitly states that the information, including exhibits, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933. Consequently, this information shall not be incorporated by reference into any other SEC filing.
Investor Verification Checklist
- Verify the specific clinical endpoints and statistical significance of the plaque psoriasis study results referenced in Exhibit 99.1.
- Review the detailed top-line data from the Phase 2b ANTHEM-UC study for ulcerative colitis in Exhibit 99.2.
- Confirm the Company's updated corporate presentation on their official website for further context on development timelines.
- Note that this 8-K does not contain financial data; refer to the most recent 10-K or 10-Q for liquidity and cash position.